Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

Lung Cancer Metastatic Clinical Trial

— SUPPRESS-NSCLC  

Official title:

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Non Small Cell Lung Cancer: A Registry-based Phase II Randomized Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04405401
• Other study ID #: 2021-9066
• Status: Recruiting
• Phase: Phase 2
• Start date: January 5, 2021
• Est. completion date: July 1, 2027

Study information

• Verified date: December 2023
• Source: Centre hospitalier de l'Université de Montréal (CHUM)
• Contact: Silvine Benth
• Phone: 514-890-8254
• Email: silvine.benth.chum[@]ssss.gouv.qc.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 68
• Est. completion date: July 1, 2027
• Est. primary completion date: July 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 years

• Metastatic NSCLC enrolled in our CRCHUM Lung Cancer Registry and co-enrolled to the PERa registry

• Ability to provide written informed consent

• Eastern Cooperative Oncology Group (ECOG) performance status 0-3

• Oligoprogression to 1-5 extracranial lesions = 5cm and involving = 3 organs. Progression at the primary tumor site should be counted within the total of 5 lesions. For patients with lymph node metastases, each node is counted as one site of metastasis.

• Oligoprogression while on ICI or TKI (any line)

• Patients with brain metastasis are allowed; brain metastasis are not counted in the maximum number of lesions and should be treated as per standard of care

• All sites of disease can, in the opinion of the investigator, be safely treated and targetable with SABR (taking into account prior local therapy, organ function and underlying medical condition such as inflammatory bowel disease, pulmonary fibrosis, etc.)

• Patients with prior metastases that have been treated with ablative therapies (e.g. radiotherapy, surgery or radiofrequency ablation) before their current line of systemic therapy, are eligible.

Exclusion Criteria:

• Any lesion beyond 5 cm

• Pregnancy or breastfeeding

• Any medical condition that could, in the opinion of the investigator, preclude radiotherapy or prevent follow-up after radiotherapy.

• Presence of spinal cord compression Metastatic disease that invades the GI tract (including esophagus, stomach, small or large bowel)

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Cancer Metastatic
• Lung Neoplasms

Intervention

Radiation:
• SABR
SABR to all oligoprogressive lesions + continuation of current systemic therapy

Other:
• Standard of care
Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.

Locations

Country	Name	City	State
Canada	Centre Hospitalier de l'Université de Montréal	Montréal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Centre hospitalier de l'Université de Montréal (CHUM)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	PFS defined from randomization to disease progression at any site or death	5 years
Primary	OS	OS defined as time from randomization to time of death from any cause.	5 years
Secondary	Quality of life Measured using the FACT-G tool, lung cancer-related patient reported outcome- CTCAE (PRO-CTCAE)	Measured using the FACT-G tool, lung cancer-related patient reported outcome- CTCAE (PRO-CTCAE)	5 years
Secondary	Quality of life 5-level EQ-5D (EQ-5D-5L)	questionnaire	5 years
Secondary	Grade = 3 toxicity	Measured using the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	5 years
Secondary	Local control	Defined as time from the end of SABR treatment to date of local failure and will be measured only in the experimental arm	5 years
Secondary	Time to next systemic therapy	Defined as time from randomization to time of subsequent therapy line	5 years